201227-39-6

Basic information

• Product Name: 5-Bromo-1H-indazole-3-carbonitrile
• Synonyms: 5-BROMO-1H-INDAZOLE-3-CARBOXYNITRILE;5-BROMO-1H-INDAZOLE-3-CARBONITRILE;5-BROMO-3-CYANOINDAZOLE;1H-INDAZOLE-3-CARBONITRILE, 5-BROMO-;5-Bromo-3-cyano-1H-indazole;3-Methyl-1H-indazole hydrochloride;5-Bromo-indazole-3-carbonitrile
• CAS NO: 201227-39-6
• Molecular Formula: C₈H₄BrN₃
• Molecular Weight: 222.04
• Product Categories: Indazole
• Mol File: 201227-39-6.mol

Chemical Properties

• Boiling Point: 425.268 °C at 760 mmHg
• Flash Point: 210.995 °C
• Appearance: /
• Density: 1.852 g/cm³
• Refractive Index: 1.739
• Storage Temp.: 2-8°C
• PKA: 9.61±0.40(Predicted)
• CAS DataBase Reference: 5-Bromo-1H-indazole-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-1H-indazole-3-carbonitrile(201227-39-6)
• EPA Substance Registry System: 5-Bromo-1H-indazole-3-carbonitrile(201227-39-6)

Safety Data

• Hazardous Substances Data: 201227-39-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1H-indazole-3-carbonitrile is used as a chemical intermediate for the synthesis of more complex chemical compounds. It plays a crucial role in the development of new pharmaceutical products, contributing to the advancement of medicine and healthcare.
Due to the limited information about its toxicity and safety, 5-Bromo-1H-indazole-3-carbonitrile requires careful handling and adherence to standard laboratory safety procedures to ensure the safety of researchers and the environment.

InChI:InChI=1/C8H4BrN3/c9-5-1-2-7-6(3-5)8(4-10)12-11-7/h1-3H,(H,11,12)

Upstream product

• 2973-50-4 2-aminophenylacetonitrile 
• 882855-95-0 2-(2-amino-5-bromophenyl)acetonitrile 
• 610-66-2 2-nitro-benzeneacetonitrile 

Relevant articles and documents

Synthetic method of 4-fluoroindazole 3-carbonitrile or derivative thereof

The invention is applicable to the technical field of chemical synthesis, and provides a synthesis method of 4-fluoroindazole 3-carbonitrile or derivatives thereof, which comprises the following steps: reacting 2-fluoro-6-nitrophenylacetaldehyde, ethanol, sodium bicarbonate, hydroxylamine hydrochloride and water to obtain 2-fluoro-6-nitrophenylethyloxime; reacting 2-fluoro-6-nitroacetoxime with acetic anhydride to obtain 2-fluoro-6-nitrophenylacetonitrile; reacting 2-fluoro-6-nitrophenylacetonitrile, tetrahydrofuran, methanol, water, ammonium chloride and iron powder, and reacting with glacialacetic acid and acetic anhydride to obtain 2-acetylamino-6-fluorophenylacetonitrile; reacting 2-acetylamino-6-fluorophenylacetonitrile, glacial acetic acid, acetic anhydride and isoamyl nitrite, andreacting with ethanol and sodium hydroxide to obtain the 4-fluoroindazole 3-carbonitrile. The synthesis method provided by the invention is mild in reaction condition and easy to operate, and the adopted raw materials are conventional and harmless.

Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3

A weak screening hit with suboptimal physicochemical properties was optimized against PFKFB3 kinase using critical structure-guided insights. The resulting compounds demonstrated high selectivity over related PFKFB isoforms and modulation of the target in

N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions there-of; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal

N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.